Glucagon like peptide 1 receptor agonists: therapy for diabetes management

Autores/as

  • Natalia Andrea Rojas Hospital Pablo Tobón Uribe
  • Elkyn Johan Granados Vega Hospital Pablo Tobón Uribe

DOI:

https://doi.org/10.21615/cesmedicina.32.1.3

Resumen

Introduction: Glucagon-like peptide 1 agonists inhibit glucose-dependent glucagon secretion, decrease gastric emptying and appetite through neural mechanisms, contribute to glucose regulation and show reduction in glycated hemoglobin A.

Methods: A bibliographic search was made on Medline® about pharmacology of the agonist glucagon-like peptide-1 receptor , Liraglutide, Lixisenatide, Albiglutide, Exenatide, Exenatide with long-acting release.

Results: The GLP1 receptor agonist are agents involved with glycemic balance, weight loss induction and are associated with lower risk of hypoglycemia. They have shown efficacy in the treatment of hypoglycemia in patients with type-2 diabetes.

Conclusions: GLP1 receptor agonist are part of the therapies for diabetes that have shown benefits in metabolic control, effectiveness in weight reduction and changes in glycated hemoglobin. More studies are needed to evaluate its long-term safety.

Descargas

Los datos de descargas todavía no están disponibles.

Biografía del autor/a

Natalia Andrea Rojas, Hospital Pablo Tobón Uribe

Química Farmacéutica

Magister en Epidemiología

Elkyn Johan Granados Vega, Hospital Pablo Tobón Uribe

Hospital Pablo Tobón Uribe

Magister en Epidemiología

Descargas

Publicado

21-11-2017

Cómo citar

Rojas, N. A., & Granados Vega, E. J. (2017). Glucagon like peptide 1 receptor agonists: therapy for diabetes management. CES Medicina, 32(1), 23–30. https://doi.org/10.21615/cesmedicina.32.1.3

Número

Sección

Revisión de tema
Estadísticas de artículo
Vistas de resúmenes
Vistas de PDF
Descargas de PDF
Vistas de HTML
Otras vistas